BioMark Diagnostics Inc.
BMKDF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $7 | $39 | $39 | $39 |
| % Growth | -82.4% | 0% | 1.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $7 | $39 | $39 | $39 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $190 | $112 | $146 | $113 |
| G&A Expenses | $178 | $180 | $244 | $139 |
| SG&A Expenses | $178 | $180 | $244 | $139 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $94 | $137 | $102 | $107 |
| Operating Expenses | $462 | $430 | $491 | $359 |
| Operating Income | -$455 | -$391 | -$452 | -$321 |
| % Margin | -6,625.1% | -1,002% | -1,160.3% | -831.3% |
| Other Income/Exp. Net | -$26 | -$25 | $31 | -$14 |
| Pre-Tax Income | -$481 | -$416 | -$422 | -$335 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$481 | -$416 | -$422 | -$335 |
| % Margin | -7,006.2% | -1,066.9% | -1,082.1% | -868.1% |
| EPS | -0.01 | -0.004 | -0.005 | -0.004 |
| % Growth | -150% | 16.7% | -23.1% | – |
| EPS Diluted | -0.01 | -0.004 | -0.005 | -0.004 |
| Weighted Avg Shares Out | 105,090 | 105,090 | 88,082 | 85,238 |
| Weighted Avg Shares Out Dil | 105,090 | 105,090 | 88,082 | 85,238 |
| Supplemental Information | – | – | – | – |
| Interest Income | $18 | $4 | $1 | $0 |
| Interest Expense | $6 | $9 | $11 | $15 |
| Depreciation & Amortization | $86 | $100 | $227 | $58 |
| EBITDA | -$389 | -$306 | -$184 | -$262 |
| % Margin | -5,654.3% | -785.8% | -471.3% | -678.3% |